Rheumatoid arthritis (RA) is the most common form of chronic inflammatory arthritis, characterized by synovitis and progressive destruction of bone and cartilage in the affected joints. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) are typically prescribed immediately after an RA diagnosis to minimize joint damage. However, some patients’ poor response to standard treatments highlights the urgent need for new therapies.
This article was originally published on MedicalXpress.com
